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Abstract
Background: Some aspects of validity are missing for the Harris Hip Score (HHS). Our objective was to examine the
clinically meaningful change thresholds, responsiveness and the predictive ability of the HHS questionnaire.
Methods: We included a cohort of patients who underwent primary total hip arthroplasty (THA) and responded
to the HHS preoperatively and at 2- or 5-year post-THA (change score) to examine the clinically meaningful
change thresholds (Minimal clinically important improvement, MCII; and moderate improvement), responsiveness
(effect size (ES) and standardized response mean (SRM)) based on pre- to post-operative change and the
predictive ability of change score or absolute postoperative score at 2- and 5-years post-THA for future revision.
Results: Two thousand six hundred sixty-seven patients with a mean age of 64 years completed baseline HHS;
1036 completed both baseline and 2-year HHS and 669 both baseline and 5-year HHS. MCII and moderate improvement
thresholds ranged 15.9–18 points and 39.6–40.1 points, respectively. ES was 3.12 and 3.02 at 2- and 5-years; respective
SRM was 2.73 and 2.52. There were 3195 hips with HHS scores at 2-years and 2699 hips with HHS scores at 5-years
(regardless of the completion of baseline HHS; absolute postoperative scores). Compared to patients with absolute
HHS scores of 81–100 (score range, 0–100), patients with scores <55 at 2- and 5-years had higher hazards
(95 % confidence interval) of subsequent revision, 4.34 (2.14, 7.95; p < 0.001) and 3.08 (1.45, 5.84; p = 0.002),
respectively. Compared to HHS score improvement of >50 points from preoperative to 2-years post-THA, lack of
improvement/worsening or 1–20 point improvement were associated with increased hazards of revision, 18.10
(1.41, 234.83; p = 0.02); and 6.21 (0.81, 60.73; p = 0.10), respectively.
Conclusions: HHS is a valid measure of THA outcomes and is responsive to change. Both absolute HHS
postoperative scores and HHS score change postoperatively are predictive of revision risk post-primary THA. We
defined MCID and moderate improvement thresholds for HHS in this study.
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Background
Total Hip Arthroplasty (THA) is the second most com-
monly performed arthroplasty in the U.S. In 2010, 438,000
THAs were done in the U.S. [1] and its utilization rate is
increasing rapidly. U.S. Medicare spent $9 billion on im-
plantable medical device procedures in 2009 [2].
The improvements in pain and function after THA are
measured with instruments such as Harris Hip Score
(HHS) [3]. HHS is the most commonly used instrument
for the assessment of outcomes post-THA [4]. HHS is
valid and reliable [5–8] and is often used as a reference/
gold standard for assessing the construct validity of
other patient-reported outcome measures (PROs) for hip
outcomes [9]. HHS is more responsive than the Western
Ontario McMaster Osteoarthritis Index (WOMAC) [8]
(a pain and function composite measure), short form-36
(SF-36) [8, 10, 11] (a generic health-related quality of life
measure) and the walking speed [11] (an objective meas-
ure). HHS is joint-specific, measures hip outcomes and
is widely available. A surgeon or a health professional
usually completes HHS.
To our knowledge, despite its widespread use, there
are no published data regarding what is a clinically im-
portant difference on the HHS or whether the HHS
scores are predictive of the risk of future revision sur-
gery. Defining clinically important thresholds for out-
comes instruments such as HHS is critical, since it has
direct clinical care and clinical trial relevance. For clin-
ical care, this threshold could define what proportion of
patients improved (by what matters to a patient, which
is more relevant than a mean change for a population
and/or a p-value for group means) with any new clinical
initiative. For a clinical trial, thresholds would allow a
comparative assessment of one intervention vs. another,
and thus allow the design of clinical trials with an ad-
equate sample size to differentiate two interventions
[12]. If HHS can predict the risk of early revision sur-
gery, future studies could assess its utility as a screening
tool for implant failures after THA. The objective of this
study was to define the clinically meaningful thresholds
for improvement and assess the responsiveness of HHS
and examine its predictive ability for early revision surgery
in patients with primary THA.
Methods
Study participants and the HHS questionnaire
The Human Ethics Committee at the Mayo Clinic ap-
proved the study and research was carried out in com-
pliance with the Helsinki Declaration. We received a
waiver of written informed patient consent for this
database study. Two study cohorts of patients who
underwent primary THA at the Mayo Clinic between
1993 and 2005 were examined: (1) patients who com-
pleted HHS at baseline and at follow-up at either 2- or
5-year (cohort 1); (2) patients who completed follow-up
HHS at either 2- or 5-year (cohort 2). All analyses were
performed for the first cohort and in addition, we per-
formed analysis of predictive ability of final postopera-
tive HHS scores at 2- and 5-years for the latter cohort.
HHS is a composite measure, with score ranging from
0 to 100, heavily weighted by pain and function; a
higher score is better. It includes four domains: pain (1
item; 44 points), physical function (7 items; 47 points), de-
formity (5 items; 5 points), and range of motion (5 items;
4 points) [3].
Responsiveness and predictive ability
Minimal clinically important improvements (MCII) and
moderate improvements were calculated by assessing
mean change from baseline to 2- and 5-year follow-up
in patients who reported “somewhat better now” or
“much better now” in response to the global question,
“Compared to before surgery, how is your hip?” at both
2- and 5-years, respectively. To assess responsiveness,
we calculated effect size (ES) and standardized response
mean (SRM). We calculated ES by dividing the change
in hip score from baseline to 2-years (or 5-years) by the
baseline standard deviation (preoperative; SD). According
to the Cohen’s rule, an ES of 0.20–0.49 represents a small
change, 0.50–0.79 a medium change, and ≥ 0.80 a large
change. The SRM is the mean change in the patient score
divided by the SD of the changed scores [13]. These ana-
lyses were performed for the cohort with pre-operative
and at least one post-operative follow-up, 2 or 5-year.
Descriptive statistics were reported as number (per-
centage) or mean (SD) as appropriate. We examined the
associations of the final HHS score at 2- or 5-years or
change in HHS score from baseline to 2- and 5-years,
with the risk of subsequent revision THA, at ≥ 731 days
post-surgery for 2-year and ≥ 1826 days for 5-year (Day
0 for all revision analyses, respectively). Final HHS
scores were categorized into ≤ 55, 56–63, 64–71, 72–80
and 81–100, based on quintiles. Only the first hip in a
patient was included for this study; patients with simultan-
eous bilateral THAs were excluded. We performed sensi-
tivity analyses by using the traditional categorization of
HHS: < 70, poor; 70–79, fair; 80–89, good; and 90–100 ex-
cellent. Improvement in HHS was categorized a priori as
≤ 0 (no improvement or worsening), 1–20, 21–50 vs. > 50,
based on clinical judgment from an orthopedic surgeon
(D.G.L), a co-author of the current study. Cox propor-
tional hazards regression was used, reporting a hazard
ratio and 95 % confidence intervals. Kaplan-Meier survival
was used to estimate implant survival based on the abso-
lute and change in HHS scores at 2- or 5-years. A p-value
of less than 0.05 was considered significant. Since death is
a competing risk, we also performed competing risk
models adjusting for death.
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Results
Cohort characteristics
Two thousand six hundred sixty-seven patients had
completed baseline HHS, of whom 1036 had completed
both baseline and 2-year HHS and 669 had completed
both baseline and 5-year HHS; 338 patients completed
all three assessments (baseline and 2- and 5-year HHS
(Fig. 1). Mean age was 64 years and 51 % were women.
The dempgraphic and clinic characteristics of two cohorts
used for (1) responsiveness, clinically important improve-
ment thresholds and change HHS scores (both pre- and
2- or 5-year post-arthroplasty scores) and (2) predictive
ability of 2- or 5-year HHS scores only, are shown in
Appendix: Table 3. The causes for early revision in the
2- and 5-year cohorts are shown in Appendix: Table 4.
Clinically important improvement thresholds for the HHS
and its responsiveness
MCII threshold for HHS ranged 15.9–18 points (Table 1);
and moderate improvement threshold was 39.6–40.1
points. We found that the effect sizes for HHS pre- to
post-THA were large, estimated at 3.12 and 3.02 at 2-, and
5-years. SRM was 2.73 and 2.52, at 2- and 5-years,
respectively (Table 1).
Predictive ability of the absolute and change HHS scores
There were 3195 hips with HHS scores at 2-years and
2699 hips with HHS scores at 5-years (regardless of the
completion of the baseline HHS). Low total HHS scores
at 2- and 5-years were associated with a higher risk of
revision surgery after each time-point (Table 2). Com-
pared to patients with follow-up HHS scores of 81–100,
patients with HHS scores < 55 at 2- and 5-years, had
4.34 and 3.08 higher hazards of revision subsequently,
both statistically significant (Table 2). Results were simi-
lar when we used the traditional clinical cut offs of < 70,
70–79, 80–89, and 90–100 (Table 2).
Compared to an improvement of > 50 points, no im-
provement/worsening HHS score, i.e., change ≤ 0, was
associated with a 18-fold increased risk (p = 0.02) at 2-
years post-primary THA and improvement of only 1–20
points with a 6-fold increased risk of revision (p = 0.10)
(Table 2). K-M graphs showed that 2-year HHS scores (p
=0.0018) was associated with revision risk and change
HHS score at 2-years seemed to be associated as well
with borderline statistical significance (p =0.062; Fig. 2a-d).
Models accounting for death as a competing risk con-
firmed findings; the total number of patients was small for
improvement (Appendix: Table 5).
Discussion
Our study is the first study to define the thresholds for
patient-relevant meaningful improvements on HHS.
These thresholds were 16–18 points for MCII and 40
points for moderate improvement. We used a patient
anchor to define these thresholds. MCII for HHS can
now be used for trial sample size calculations and
comparative effectiveness studies in THA. The use of
MCII in arthroplasty trials will allow future trials to be
adequately powered to examine group-level differences
in patient-level outcome assessment on HHS. This
information will compliment the mean HHS score
comparisons, an approach that combines responders
and non-responders in a single group. Consensus rec-
ommendations from an international pain trial group
are to report both means and %responders in clinical
trials, where pain is one of the primary outcomes [14].
Similar thresholds have been reported for another in-
strument, the Mayo Hip Score [15], that is patient-
administered, not physician-reported.
Our MCII threshold is similar to/lower than MCII es-
timates for other 0–100 pain scales, for example, the
thresholds of 15–20 mm on WOMAC pain [16],
24 mm on HOOS pain [17], 20 mm on VAS pain in
pain trials [18] and 22 mm on VAS pain in gout trials
[19]. This finding establishes the sensitivity to change
for HHS, an important property for an instrument.
Moderate improvement reported in our study are similar
to the substantial improvement of 50 % in pain [14, 18]
and to American College of Rheumatology (ACR50)
response in patients with rheumatoid arthritis, i.e., 50 %
improvement in composite criteria [20]. An earlier study
2-yr HHS only 5-yr HHS only Pre- and 2-yr HHS Pre- and 5-yr HHS









Incomplete, n=2,887     
No data, n=5,293
Died, n=528 
Incomplete, n=2,625      
No data, n=5,662
Fig. 1 Patient selection for cohorts requiring only 2/5-year HHS scores and those requiring both preoperative and 2/5-year scores
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in revision THA that did not use a patient anchor defined
the MCII using a statistical definition and reported it to
be 2.44 points [10], much lower than the 20-unit thresh-
old previously defined on 0–100 pain scales in trials of
chronic pain [18] and gout [19]. This might be due to very
low variability on HHS in this small sample, and is dis-
cordant with available literature for other similar pain
scales. A 2 mm improvement on a 0–100 scale (~2–4 %
change depending on the baseline) does not mean much
to patients or providers, and in most instances will be in-
distinguishable from baseline noise.
We found that HHS scores < 55 at 2- and 5-years as
well as the lack of improvement or worsening on change
HHS scores from baseline to 2-years were each predict-
ive of early revision in patients with primary THA. This
is a new finding, to our knowledge. The robustness of
this finding is supported by the consistency of estimates
at both 2- and 5-years. Our finding links HHS at early
follow-up to future implant failure and indicates that
absolute HHS scores and its trajectory post-THA may
help to screen early implant failures after primary THA.
More research is needed to see if risk prediction models
using PROs such as HHS can be developed for early im-
plant failure and validated, similar to a proposal based
on Oxford scores [21].
Wright et al. reported ES and SRM of 2.5 and 1.8 for
HHS in a sample of 78 THA patients at 6-month post-
surgery [8], confirmed in our study and extended to a
longer follow-up. A previous study showed a much lar-
ger effect size of 8.6 for HHS in patients with revision
THA [10]; SRM in hip fracture was 0.75 for HHS [22].
Some reasons for the difference in findings from our
study vs. previous study for HHS effect size were the dif-
ference in patient population (primary THA vs. revision
THA), length of follow-up (up to 5-years vs. 6 months),
and the setting (USA vs. China).
Our study strengths include a large primary THA pa-
tient sample from a Joint Registry, the use of well-
Table 1 Responsiveness of the Harris Hip Score (HHS) and thresholds for clinically important differences on the HHS
2-year - Baseline value [#patients] 5-year - Baseline value [#patients]
Responsiveness (Discriminant Ability)
Effect Size (ES) 3.12 [n = 1036] 3.02 [n = 669]
Standardized Response Mean (SRM) 2.73 [n = 970] 2.52 [n = 637]
Clinically Important Improvement, Mean (Standard deviation)
Minimal Clinically important Improvement (MCII) 18.0 (18.2) [n = 59] 15.9 (19.8) [n = 39]
Moderate improvement 40.1 (12.8) [n = 911] 39.6 (13.5) [n = 598]
Table 2 Predictive ability of HHS: Association of HHS scores at 2- and 5-years with the risk of revision in patients with THA
Hazards of THA Revision (95 % CI) P-value* Hazards of THA Revision (95 % CI) P-value*
2-year data 5-year data
N = 3151 with 88 events N = 2461 with 71 events
Harris Hip Score categories
≤ 55 vs. 81–100 4.34 (2.14, 7.95) < 0.001 3.08 (1.45, 5.84) 0.002
56–63 vs. 81–100 1.31 (0.36, 3.32) 0.62 1.25 (0.34, 3.20) 0.69
64–71 vs. 81–100 1.80 (0.59, 4.18) 0.23 0.64 (0.07, 2.36) 0.60
72–80 vs. 81–100 0 (0, 0.5) 0.006 1.13 (0.37, 2.66) 0.80
Harris Hip Score clinical categories
< 70 vs. 90–100 2.32 (1.32, 3.85) 0.002 1.60 (0.84, 2.85) 0.14
70–79 vs. 90–100 0 (0, 0.5) 0.005 1.18 (I0.38, 2.79) 0.74
80–89 vs. 90–100 0.67 (0.33, 1.23) 0.23 0.66 (0.30, 1.30) 0.27
N = 1011 with 13 events** N = 583 with 5 events**
Improvements in Harris Hip Score
≤ 0 vs. 51–75 18.10 (1.41, 234.8) 0.02 2.20 (0.02, 29.01) 0.68
1–20 vs. 51–75 6.21 (0.81, 60.73) 0.10 0.71 (0.005, 8.78) 0.85
21–50 vs. 51–75 2.19 (0.50, 20.55) 0.41 0.62 (0.12, 3.92) 0.64
*P-value was calculated using a Cox proportional hazards regression model
**The main reason for decrease in the number of patients between absolute score (top) and change HHS score analyses (bottom) was that a lower number
completed both surveys (See Fig. 1 for details)
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accepted methods to examine validity, the performance
of sensitivity analyses and robustness of estimates across
2- and 5-year data.
Our study has several limitations. MCII thresholds
are not absolute, but rather estimates and can vary
somewhat from one population to another, and be-
tween studies. Our findings were derived from a single
center primary THA cohort, and our patient character-
istics are similar to several other THA studies including
the one with a national sample [23–25], implying that
our sample is representative of primary THA. However,
findings may not be generalizable to revision THA.
However, more studies in other populations can deter-
mine the slight variation in MCII thresholds or confirm
that these thresholds hold true for those groups as well.
Incorporation of 2- or 5-year HHS scores into surgeon’s
clinical decision-making may have biased findings to be
more significant that they actually might be. However,
many revisions occurred at a time much after the
assessments, and it is possible that the surgeon did not
access old scores. We recognize that radiographic
changes after arthroplasty are very important in decid-
ing whether revision surgery is needed or not, since
asymptomatic patients sometimes show loose hip im-
plants. The present study did not assess the predictive
ability of hip radiographs alongside Harris Hip Score.
This should be investigated in future studies. Our study
establishes the thresholds for clinically meaningful
change on HHS; however, ceiling effects have been
noted with HHS [26].
Conclusions
In conclusion, we found that in patients who underwent
primary THA, HHS was responsive to change and pre-
dictive of the risk of revision after primary THA. Clinically
important improvement thresholds for minimal and
moderate clinically important improvements on HHS
were defined in this study can now be used in arthroplasty
clinical trials and clinical care. This report also establishes
an additional utility of HHS, in predicting early revision
surgery after THA, an important outcome.
Fig. 2 Implant survival is shown for different categories of absolute (panels a and b) or change HHS scores (panels c and d), with follow-up up to
10 years post-THA. Follow-up starts at ≥ 731 days post-surgery for 2-year and ≥ 1826 days for 5-year (Day 0 for all revision analyses), i.e., only after
the administration of the 2- and 5-year HHS survey
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Table 3 Demographics of the study populations
Hips with HHS preoperatively
(n = 2667)
Hips with HHS preoperative
and 2 years (n = 1036)
Hips with HHS preoperative
and 5 years (n = 669)
Age in years, Mean (SD) 64 (14) 65 (13) 64 (13)
Male, n (%) 1315 (49.3 %) 501 (48.4 %) 317 (47.4 %)
Age Groups, n (%)
< = 60 years 889 (33.3 %) 316 (30.5 %) 224 (33.5 %)
61–70 years 754 (28.3 %) 291 (28.1 %) 196 (29.3 %)
71–80 years 894 (30.2 %) 325 (31.4 %) 206 (30.8 %)
≥ 81 years 220 (8.2 %) 104 (10.0 %) 43 (6.4 %)
Body Mass Indexa, n (%)
< 25 kg/m2 587 (22.2 %) 215 (20.8 %) 160 (24.1 %)
25–29.9 kg/m2 1032 (38.9 %) 414 (40.2 %) 258 (38.8 %)
30–34.9 kg/m2 646 (24.4 %) 262 (25.4 %) 159 (23.9 %)
35–39.9 kg/m2 235 (8.9 %) 92 (8.9 %) 56 (8.4 %)
≥ 40 kg/m2 150 (5.7 %) 48 (4.7 %) 32 (4.8 %)
American Society of Anesthesiologists Class (ASA)b, n (%)
Class I-II 1654 (62.1 %) 645 (62.4 %) 444 (66.5 %)
Class II-IV 1008 (37.9 %) 388 (37.6 %) 224 (33.5 %)
Deyo-Charlson Index, mean (SD) 1.1 (2.0) 1.1 (1.9) 1.0 (1.9)
Psychological Comorbidity, n (%)
Anxiety 135 (5.1 %) 47 (4.5 %) 30 (4.5 %)
Depression 231 (8.7 %) 78 (7.5 %) 50 (7.5 %)
Total number of Joints Replaced
1 2159 (81.0 %) 824 (68.5 %) 525 (78.5 %)
2 463 (17.4 %) 194 (18.7 %) 135 (20.2 %)
3 38 (1.4 %) 15 (1.4 %) 6 (0.9 %)
4 7 (0.3 %) 3 (0.3 %) 3 (0.4 %)
Underlying Diagnosis, n (%)
Osteoarthritis 2404 (90.1 %) 952 (91.9 %) 598 (89.4 %)
RA/Inflammatory Arthritis 49 (1.8 %) 18 (1.7 %) 14 (2.1 %)
Other 214 (8.0 %0 66 (6.4 %) 57 (8.5 %)
Missing data for preoperative, preoperative and 2-year and preoperative and 5-year HHS cohorts were as follows
aFor BMI, there were 17, 5 and 4 missing cases, respectively
bFor ASA, there were 5, 3 and 1 missing cases, respectively
Table 4 Causes for early revision in patients with HHS data
2-years cohort 5-years cohort
N = 403 revisions N = 282 revisions
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